An Open-Label, Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Single-Dose Of Omaveloxolone In Children ≥2 To <16 Years Of Age With Friedreich's Ataxia
Latest Information Update: 16 Jun 2025
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen; Reata Pharmaceuticals
Most Recent Events
- 21 May 2025 Given protocol has been amended as above-1) Number of treatment arms has been changed from 4 to 7. 2) Primary endpoints has been amended.3) Planned number of patients has been changed from 20 to 35.
- 21 May 2025 Planned number of patients changed from 20 to 35.
- 08 Jul 2024 Status changed from not yet recruiting to recruiting.